{"ticker": {"uuid": "fea6d02a-3fdd-4ea7-afb9-c0a519eabacf", "symbol": "CLLS", "name": "Cellectis SA", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of \"Moderate Buy\" from Brokerages", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOczJtYWo5bG5VZnJIQ0sxSVB3S1FPNWRjSFVrdVpKV2tqREgwYjRCQU9BTDZVbEItd21maF8ybG5UVEhWZ3dRdHlzRVRzN1o2ZGxNMk9ma1E5djUxaXJqS2hyaUQ3ODg2Z2hvOGp0RVpXaF9pUF9QQnFDRnZfemRVRHRWQkhiVkpUUERYZWlpaEZDcEFBYnBEYlB0TWEzMU41c3lmMmF0TzBNZk1ySVpLNnBXOTRneHczem9BTU5Ec3NoRjRkbGVQZUZkNjhxbGxmbDdfZVpNa2c?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T10:25:36+00:00", "published_display": "17 Jul 2026 10:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cellectis S.A. Sponsored ADR Stocks", "summary": "This article lists ETFs that include Cellectis S.A. Sponsored ADR stocks. It highlights the iShares Biotechnology ETF (IBB) as one such fund, providing its market value, weight, issuer, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/etfs/", "source_name": "TradingView", "published_at": "2026-07-16T21:39:46", "published_display": "16 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics", "summary": "DelveInsight's \"Multiple Myeloma Pipeline Insight, 2026\" report highlights the extensive global effort to develop new therapies for Multiple Myeloma, with over 75 companies and 80+ treatments in various stages of development. Recent clinical trial advancements emphasize the effic", "url": "https://www.barchart.com/story/news/3173295/multiple-myeloma-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-bluebird-bio-cellectis-sa-caribou-biosciences-luminary-therapeutics-poseida-therapeutics", "source_name": "Barchart", "published_at": "2026-07-08T01:10:47", "published_display": "08 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Edges Lower as Biotech Stock Tests Key Support Near $3.06 - Point of Control", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPdTNGcTNReFpqU1FfeGEtM2JVSHpGdU8tNVpNbldLYy1HbWVTSm8zRWNCcDdPYUEzdUczdi16ck1CZDF0SjNNMm5nVXRKVGExWE05V2l5XzZzdW5kblFCbUtiVU5ESDI5T1JKVV93SGlhNG85R3hyUEt2c1plSG5jRm0zcldOSzVpeG51YlRWdEcta3pGWmJqQUVfMVNuREhZRjlseG9PeDFWd0hibVRfQ0ROY24?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T21:40:31+00:00", "published_display": "07 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article provides the \"Price to book forward\" for Cellectis S.A. (Euronext: ALCLS). It indicates the financial metric for the company, accessible through TradingView's platform, and details the data sources for market and reference information. The content itself seems to be ", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:40:58", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article focuses on the enterprise value to revenue forward for Cellectis S.A. (Euronext: ALCLS). The content, likely a financial data point or an analysis snippet, is presented within the context of TradingView's financial market platform.", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T14:10:21", "published_display": "05 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cellectis S.A. \u2013 NASDAQ:CLLS", "summary": "This page provides financial information for Cellectis S.A. (NASDAQ: CLLS), specifically its price-to-book forward ratio. It briefly touches on the company's market data but does not include further details like the actual value or changes in the price-to-book ratio. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:40:20", "published_display": "05 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis monthly capital update shows 100.7M shares, 105.6M votes", "summary": "Cellectis (CLLS) released its monthly capital update for June 30, 2026, reporting 100,698,158 shares outstanding and 105,551,650 voting rights on Euronext Growth. This update provides transparency on the company's capital structure, as required by the French financial markets aut", "url": "https://www.stocktitan.net/news/CLLS/monthly-information-on-share-capital-and-company-voting-l52vb3ylahym.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:23", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European ADRs Jumped As Biotech Led The Pack", "summary": "European ADRs, representing foreign shares traded in the US, experienced a significant jump led by biotech companies. The S&P Europe Select ADR Index rose 2.21%, with Cellectis climbing 14% and BioNTech gaining 4.5%. This rise in ADRs can act as a \"preview\" for European markets w", "url": "https://finimize.com/content/european-adrs-jumped-as-biotech-led-the-pack", "source_name": "Finimize", "published_at": "2026-07-02T15:40:23", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings", "summary": "This page provides an extensive list of financial disclosures and SEC filings for Cellectis S.A. (CLLS), including earning reports, corporate presentations, and annual reports dating back to 2022. It highlights key events such as clinical trial progress for UCART22, cash runway u", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/documents/", "source_name": "TradingView", "published_at": "2026-07-01T21:12:21", "published_display": "01 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article displays the \"Price to earnings forward\" metric for Cellectis S.A. (Euronext:ALCLS) on the TradingView platform. The content is primarily a data placeholder within a financial information service, showing the company's ticker, market status, and indicating that the s", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T23:39:48", "published_display": "30 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article provides a brief mention of the \"Price to sales forward\" for Cellectis S.A. (EURONEXT:ALCLS) on the TradingView platform. It appears to be a stub or a section of a larger financial data presentation, indicating the availability of this specific financial metric. The ", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T17:42:27", "published_display": "30 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cellectis S.A. \u2013 FWB:ZVA", "summary": "This article provides the \"Price to earnings forward\" value for Cellectis S.A. (FWB:ZVA) on the Frankfurt Stock Exchange. It indicates that no trades have occurred and the market is closed. The content primarily focuses on financial data for this specific company.", "url": "https://www.tradingview.com/symbols/FWB-ZVA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:40:22", "published_display": "30 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis S.A. Actuals & Estimates (EURONEXT:ALCLS)", "summary": "This article provides comprehensive financial data and analyst estimates for Cellectis S.A. (ALCLS) on EURONEXT. It details current stock performance, historical highs and lows, market capitalization, volatility, and future price forecasts from analysts. The report also includes ", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:51", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders of Cellectis (NASDAQ: CLLS) reject savings plan issue", "summary": "Cellectis S.A. filed an amended Form 6-K to correct a clerical error regarding its Combined General Meeting of Shareholders on June 25, 2026. The amendment clarifies that Resolution 30, which dealt with delegating authority to increase share capital for an employee savings plan, ", "url": "https://www.stocktitan.net/sec-filings/CLLS/6-k-a-cellectis-s-a-amended-current-report-foreign-issuer-d318a961cebc.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:51", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cellectis S.A. (ZVA) stock, including analyst price targets, future earnings estimates, and historical price data. It details the company's financial metrics such as recent earnings per share, revenue, and net income, alongside its EBITDA and ", "url": "https://www.tradingview.com/symbols/SWB-ZVA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:37", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS)", "summary": "This article provides an overview of Cellectis S.A. (NASDAQ:CLLS) financial actuals and estimates as presented on TradingView. It highlights different financial statements like the income statement, balance sheet, and cash flow, allowing users to compare actual results with analy", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:41:37", "published_display": "26 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026", "summary": "Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted, and resolution 30 was rejected. Approximately 55.84% of voting rights were exercised, and the detailed results are available on the company's website. Cellectis is a cli", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317953/0/en/Cellectis-Reports-Results-from-Shareholders-Meeting-Held-on-June-25-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T08:41:30", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Cellectis Reports Results From Shareholders Meeting Held on June 25, 2026", "summary": "Cellectis has reported the results of its Shareholders Meeting held on June 25, 2026. The meeting discussed and approved key resolutions regarding the company's governance and financial matters for the upcoming period.", "url": "https://www.moomoo.com/news/post/72057120/press-release-cellectis-reports-results-from-shareholders-meeting-held-on", "source_name": "Moomoo", "published_at": "2026-06-25T22:40:23", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Shareholders Approve 2025 Accounts and Expand Capital-Raising Powers at June 25 Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPSmxLVDdKSExuTnlmSUxONHlBNEpMWU9LZ21LbjZQNXIxd2NNSkU2bTZVTEp5WUZDVDF3RHpfUU9VZ09oNlVOdUg2VlROMkpqa05hVU4tbUQyNjZ2OEk2Wk1QUno0ZXR3TW5ocXFLcW1jdFQ5MFNESVNsQzIxYmE1UWxYZHlhNzNBZkF5VDh1TV9Ic0NHRWhuc0dSVTIzRnU4V2tIdUtxTmlnQzdBeE9iMTYyYkF4c2RTd3RBU2o4b2drWFd4V2NXRExzNHVRc0NBbUw4dmtwZVJxRG1zRUp0WFdSVQ?oc=5", "source_name": "TipRanks", "published_at": "2026-06-25T21:30:41+00:00", "published_display": "25 Jun 2026 21:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) meeting backs capital issuance mandates but rejects employee savings share plan", "summary": "Cellectis S.A. held its Combined General Meeting of Shareholders on June 25, 2026, where key financial items and capital increase delegations, including an \u201cat-the-market\u201d equity financing program on the U.S. market, were approved with strong shareholder support. Shareholders als", "url": "https://www.stocktitan.net/sec-filings/CLLS/6-k-cellectis-s-a-current-report-foreign-issuer-9221cfa967a0.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:08", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Cellectis S.A. Current Report (Foreign Issuer) | CLLS SEC Filing - Form 6-K", "summary": "Cellectis S.A. filed a Form 6-K reporting the results of its shareholders' general meeting held on June 25, 2026. The company announced that resolutions 1 through 29 were adopted, while resolution 30 was rejected, aligning with the board of directors' recommendations. Approximate", "url": "https://www.stocktitan.net/sec-filings/CLLS/6-k-cellectis-s-a-current-report-foreign-issuer-e3049933ddcc.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:08", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis SA (CLLS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cellectis SA (CLLS), highlighting its current earnings forecast score, average price target from analysts, and expected revenue for the next quarter. It details analyst ratings, revealing a \"Buy\" trend based on 7 analysts, and includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clls/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:53", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) 10K Form and Latest SEC Filings 2026", "summary": "This article provides an overview of Cellectis (CLLS) SEC filings, including a historical record of documents submitted since 2017. It details the types of filings such as 10-K, 10-Q, and 8-K, explaining their significance for investors. The article notes that Cellectis's most re", "url": "https://www.marketbeat.com/stocks/NASDAQ/CLLS/sec-filings/", "source_name": "MarketBeat", "published_at": "2026-06-12T03:09:34", "published_display": "12 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis reports strong CAR-T cancer trial data at EHA 2026", "summary": "Cellectis (NASDAQ:CLLS) presented highly encouraging clinical trial data at the EHA 2026 Congress for its gene-edited, off-the-shelf CAR-T cancer therapies. The company reported a 100% overall response rate for its lead asset, lasme-cel, in a target group of leukemia patients, wi", "url": "https://grafa.com/en/news/united-states/cellectis-cancer-car-t-data-eha-leukemia-lymphoma", "source_name": "grafa.com", "published_at": "2026-06-11T12:39:51", "published_display": "11 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis CAR-T trials show responses in heavily pretreated blood cancers", "summary": "Cellectis presented final Phase 1 results for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia and preliminary data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026. Lasme-cel achieved a 100% overall response rate in the target Phase ", "url": "https://www.stocktitan.net/news/CLLS/cellectis-presents-final-phase-1-results-of-lasme-cel-and-5f46wwlvd8bl.html", "source_name": "Stock Titan", "published_at": "2026-06-11T06:39:51", "published_display": "11 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress", "summary": "Cellectis presented final Phase 1 data from the BALLI-01 clinical trial for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), showing a 100% overall response rate in the target Phase 2 population. Additionally, preliminary results from the NATHALI-", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310207/0/en/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-eti-cel-at-eha-2026-congress.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T06:39:51", "published_display": "11 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at ...", "summary": "Cellectis presented final Phase 1 data for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and preliminary data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) at the EHA 2026 Annual Congress. The lasme-cel trial showed ", "url": "https://www.caledonianrecord.com/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-eti-cel/article_0acd33b4-1689-52a4-904d-19013a432ae6.html", "source_name": "Caledonian Record", "published_at": "2026-06-11T06:39:51", "published_display": "11 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biggest stock movers Wednesday: CBRL, CLLS, SMCI, trucking stocks, and more (SMCI:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNa3V5YURYTDk4RzRmak1hRE5XTzhOQkZlekt5WTB1T2xDLUhQSTBsVXJVMEd5c1YxS21qNDgxMldpeDlhbWpkTFRlemlTVXNySmNUYUMtWFJGZnBQQURKZWJHVVNaVG02dngxR3l0YThfcU9VWFAyeXgxUGE1SVJfT2swbkRUbVBWQW90cVd3bG1EQld3ZktWZ0doZVpUaVRFMWhJNE1TQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis: FDA Grants RMAT Status to Lasm\u00e9-cel for B-Cell ALL Leukemia", "summary": "The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status to Cellectis' lasm\u00e9-cel, an allogeneic CAR-T candidate, for treating relapsed or refractory B-cell acute lymphoblastic leukemia. This designation is based on promising phase 1 data from the BALLI-01 trial, p", "url": "https://www.ideal-investisseur.fr/en/stock-news/cellectis-fda-grants-rmat-status-to-lasme-cel-for-b-cell-all-leukemia/20642.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-10T07:10:56", "published_display": "10 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQelRyblNBOE01OEh0TlZnYkJJRGE2UEl0RW1nZ0RxeHk3aWpmTU9iUllYY0F0N0FMR3A4VVJEYl9GT0NSdzBObloyVTBnQmZHQkZBdkhFVTNCdHQyZkRjOTh2V0xXNUp1cDJPUFFSdUxlSkpHd0t3TkJvUWlPdDhyd3c4Mm81QTdLUFVBaTdqYU1LNVpPTndiX1dQZWcxOVNlMkl3OTFoVko2MXJLVkZzbWRsQUliemJSMHRWTTJQVVpUZw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis now has 100,691,658 shares and 106,134,467 voting rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQkg4UndUcFVJUHNzQ1JPNmk2bk1fNGlmQ19SNENiTWYzcFB0ZW5oMC1jdzVJOTUxZWxGWUsteU9DNjhMQVBhcWV4TUNfVzhORjZFT25yVnVLSGFaZnphc2tQdGhRR29OQWJoUFVwbTJiNVFudVl2aFpORWRIX0xIb3FNZFJjeTdNVXZQLXU3cjl6Q3pHc0hsSVR5NFEwVUNkZnJIVEdVN2FGNzREdVBj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Slides 3% as Biotech Faces Resistance Near $3.70 - Overbought Signal Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQNUJobHYzR0JELVRNdEV4X1IzRkprYWJOeVZobEE3R0ljcDJDYWtOSF9hT0xMNzB2V0FxTzBNcGtMM18tcjI3bXg0SURubGFFQ1B2VHcwTXl5ZFlpZ0E3LWZwUG91ejRHRU5XT3JTSUVKYU15Ni1Kek9yWlRPNVkzSjNVV0pfbnZGR3gtbXUyNTYwYTNxRFlmY0E2NVJIQmlUOTJyeA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene-editing biotech Cellectis plans June 25 shareholder meeting in Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPMmNreTFZNF85bEI0QmwyM3o5VTczM2lPRzlTWFRpQkNTRTBORUFnbjYyMmRRWnc4QWJMeXpDYS1Sc2NLR3VsNlYwY3FOVFhCcDNxS1VwWXRFNTlwUWQxTTA3bFg0Tm9UMUV3VmFXdWNqUXNoOFpZclBoaXBZd1lPc0FXNUphYmZYLXNsRTBVcGF1djNuTmZ4em9CeTVoWUdkS1NIeU54MVB1UlB2dlI0cnFCbmRwUTBSZWJKZjcxQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cellectis stock rating held at outperform on allogeneic platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQN0I2VFNTNHpONE12eFkwemt2VzJ3RzJpb1lsOGYzd3dHdHdESDZXbVBvY0ZpUFRmSGFWUlRFa0dYUHJjNGVMYmdORmUydU9QejBxWUJRM3ZTbzg4U0p1ZlNGakNDd2ZfOTRNdVFROEt4WDVOZENGa21NRXY3bklFOW43ci1CcnF4YkhHZDdoSm12QVcyWTBybndSY1lHSWtOUUlTNkZKRE9UR2F5TkV4UUI3Y2pHLUx0b3hhcVVIWjNxQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNRjRNdzRzX1JZWnlEYmk5cE82RE9aWi1menNIaGYyYXFhMU1CU0F5LVZuX2NmN3owOWlBTnozX0dlOFRuTkxLMVhBNjEyYUk1MHZyUS0wOElNYUljWFdCYTgya3BZbnhUVVlzcmpKSG1wWG9xbW1SZ3llUE5ERVp6dnRlVzlUT0pIV05FbE5UdkVXY3J4cG81SnBSTQ?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca, Cellectis targeted in patent lawsuit over gene-editing technology", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQbXQyT3hRUGZVd0FBNjdhOGVMeVFhTm90d3lrMnVZNExaN2NQZWdLWTFCeTJRb3hwamd1UHdEaVpQeW1zTVNNX3o5ckdTZHhtdzBMWWtsRU96R0FDZXhtbDRqT1Q0VzB6d1pudVRabWNWdWN0dmFmS2I1YnZ1V3NkQ2luRW5XQ08zY2JJWmNQc1B4Umd5b1doS21HTFpEdWw3ZTVlRXJBOWdKRGI0MDJpQk9XSnN6dm5WOFIzYnN3NG9JWDBlblE?oc=5", "source_name": "Reuters", "published_at": "2025-09-26T07:00:00+00:00", "published_display": "26 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Stock Forecast and Price Target 2026 $CLLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE82cGMtNzE2UG9LamZvMENoSWg3VDRYZkZBVGVMYmNGMEMzRUR5b2dpUnMtSm1MVnpTaF9lbTc1MWk0MkE2cWd2MmxTVEhOdUlxVEVNMnVGSnZBV0tRdWdYc0ZaX0tBdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:07:11+00:00", "published_display": "11 May 2024 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9rSjlsb3JLdExuT2g0XzhZY1c4N1IxN2t5RDdPU3BDSFJhUDJtRFBPWS1kdzNkNE5HNTZjbk9HaWZfNW54bXpFR04wbmtZQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-02T23:41:02+00:00", "published_display": "02 Sep 2020 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Stock Price, News & Analysis $CLLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE44ZWE1M3RvZjlVVGFIUjZRbC1BMjBLU3gzcVpyV3lkc0Z1Ynctc0ozVjREdWxZQVh5aE9HZ0R2c3NmTEk3QlNQc3NiYXJYX2JmZGNPVGpkakpoUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T02:21:20+00:00", "published_display": "12 Aug 2016 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of \"Moderate Buy\" from Brokerages", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOczJtYWo5bG5VZnJIQ0sxSVB3S1FPNWRjSFVrdVpKV2tqREgwYjRCQU9BTDZVbEItd21maF8ybG5UVEhWZ3dRdHlzRVRzN1o2ZGxNMk9ma1E5djUxaXJqS2hyaUQ3ODg2Z2hvOGp0RVpXaF9pUF9QQnFDRnZfemRVRHRWQkhiVkpUUERYZWlpaEZDcEFBYnBEYlB0TWEzMU41c3lmMmF0TzBNZk1ySVpLNnBXOTRneHczem9BTU5Ec3NoRjRkbGVQZUZkNjhxbGxmbDdfZVpNa2c?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T10:25:36+00:00", "published_display": "17 Jul 2026 10:25", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cellectis S.A. Sponsored ADR Stocks", "summary": "This article lists ETFs that include Cellectis S.A. Sponsored ADR stocks. It highlights the iShares Biotechnology ETF (IBB) as one such fund, providing its market value, weight, issuer, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The informatio", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/etfs/", "source_name": "TradingView", "published_at": "2026-07-16T21:39:46", "published_display": "16 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics", "summary": "DelveInsight's \"Multiple Myeloma Pipeline Insight, 2026\" report highlights the extensive global effort to develop new therapies for Multiple Myeloma, with over 75 companies and 80+ treatments in various stages of development. Recent clinical trial advancements emphasize the effic", "url": "https://www.barchart.com/story/news/3173295/multiple-myeloma-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-bluebird-bio-cellectis-sa-caribou-biosciences-luminary-therapeutics-poseida-therapeutics", "source_name": "Barchart", "published_at": "2026-07-08T01:10:47", "published_display": "08 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Edges Lower as Biotech Stock Tests Key Support Near $3.06 - Point of Control", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPdTNGcTNReFpqU1FfeGEtM2JVSHpGdU8tNVpNbldLYy1HbWVTSm8zRWNCcDdPYUEzdUczdi16ck1CZDF0SjNNMm5nVXRKVGExWE05V2l5XzZzdW5kblFCbUtiVU5ESDI5T1JKVV93SGlhNG85R3hyUEt2c1plSG5jRm0zcldOSzVpeG51YlRWdEcta3pGWmJqQUVfMVNuREhZRjlseG9PeDFWd0hibVRfQ0ROY24?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T21:40:31+00:00", "published_display": "07 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article provides the \"Price to book forward\" for Cellectis S.A. (Euronext: ALCLS). It indicates the financial metric for the company, accessible through TradingView's platform, and details the data sources for market and reference information. The content itself seems to be ", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T00:40:58", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article focuses on the enterprise value to revenue forward for Cellectis S.A. (Euronext: ALCLS). The content, likely a financial data point or an analysis snippet, is presented within the context of TradingView's financial market platform.", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T14:10:21", "published_display": "05 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cellectis S.A. \u2013 NASDAQ:CLLS", "summary": "This page provides financial information for Cellectis S.A. (NASDAQ: CLLS), specifically its price-to-book forward ratio. It briefly touches on the company's market data but does not include further details like the actual value or changes in the price-to-book ratio. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:40:20", "published_display": "05 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis monthly capital update shows 100.7M shares, 105.6M votes", "summary": "Cellectis (CLLS) released its monthly capital update for June 30, 2026, reporting 100,698,158 shares outstanding and 105,551,650 voting rights on Euronext Growth. This update provides transparency on the company's capital structure, as required by the French financial markets aut", "url": "https://www.stocktitan.net/news/CLLS/monthly-information-on-share-capital-and-company-voting-l52vb3ylahym.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:23", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European ADRs Jumped As Biotech Led The Pack", "summary": "European ADRs, representing foreign shares traded in the US, experienced a significant jump led by biotech companies. The S&P Europe Select ADR Index rose 2.21%, with Cellectis climbing 14% and BioNTech gaining 4.5%. This rise in ADRs can act as a \"preview\" for European markets w", "url": "https://finimize.com/content/european-adrs-jumped-as-biotech-led-the-pack", "source_name": "Finimize", "published_at": "2026-07-02T15:40:23", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings", "summary": "This page provides an extensive list of financial disclosures and SEC filings for Cellectis S.A. (CLLS), including earning reports, corporate presentations, and annual reports dating back to 2022. It highlights key events such as clinical trial progress for UCART22, cash runway u", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/documents/", "source_name": "TradingView", "published_at": "2026-07-01T21:12:21", "published_display": "01 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article displays the \"Price to earnings forward\" metric for Cellectis S.A. (Euronext:ALCLS) on the TradingView platform. The content is primarily a data placeholder within a financial information service, showing the company's ticker, market status, and indicating that the s", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T23:39:48", "published_display": "30 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cellectis S.A. \u2013 EURONEXT:ALCLS", "summary": "This article provides a brief mention of the \"Price to sales forward\" for Cellectis S.A. (EURONEXT:ALCLS) on the TradingView platform. It appears to be a stub or a section of a larger financial data presentation, indicating the availability of this specific financial metric. The ", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T17:42:27", "published_display": "30 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cellectis S.A. \u2013 FWB:ZVA", "summary": "This article provides the \"Price to earnings forward\" value for Cellectis S.A. (FWB:ZVA) on the Frankfurt Stock Exchange. It indicates that no trades have occurred and the market is closed. The content primarily focuses on financial data for this specific company.", "url": "https://www.tradingview.com/symbols/FWB-ZVA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:40:22", "published_display": "30 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis S.A. Actuals & Estimates (EURONEXT:ALCLS)", "summary": "This article provides comprehensive financial data and analyst estimates for Cellectis S.A. (ALCLS) on EURONEXT. It details current stock performance, historical highs and lows, market capitalization, volatility, and future price forecasts from analysts. The report also includes ", "url": "https://www.tradingview.com/symbols/EURONEXT-ALCLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:51", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders of Cellectis (NASDAQ: CLLS) reject savings plan issue", "summary": "Cellectis S.A. filed an amended Form 6-K to correct a clerical error regarding its Combined General Meeting of Shareholders on June 25, 2026. The amendment clarifies that Resolution 30, which dealt with delegating authority to increase share capital for an employee savings plan, ", "url": "https://www.stocktitan.net/sec-filings/CLLS/6-k-a-cellectis-s-a-amended-current-report-foreign-issuer-d318a961cebc.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:51", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZVA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cellectis S.A. (ZVA) stock, including analyst price targets, future earnings estimates, and historical price data. It details the company's financial metrics such as recent earnings per share, revenue, and net income, alongside its EBITDA and ", "url": "https://www.tradingview.com/symbols/SWB-ZVA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:37", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS)", "summary": "This article provides an overview of Cellectis S.A. (NASDAQ:CLLS) financial actuals and estimates as presented on TradingView. It highlights different financial statements like the income statement, balance sheet, and cash flow, allowing users to compare actual results with analy", "url": "https://www.tradingview.com/symbols/NASDAQ-CLLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:41:37", "published_display": "26 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026", "summary": "Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted, and resolution 30 was rejected. Approximately 55.84% of voting rights were exercised, and the detailed results are available on the company's website. Cellectis is a cli", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317953/0/en/Cellectis-Reports-Results-from-Shareholders-Meeting-Held-on-June-25-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T08:41:30", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Cellectis Reports Results From Shareholders Meeting Held on June 25, 2026", "summary": "Cellectis has reported the results of its Shareholders Meeting held on June 25, 2026. The meeting discussed and approved key resolutions regarding the company's governance and financial matters for the upcoming period.", "url": "https://www.moomoo.com/news/post/72057120/press-release-cellectis-reports-results-from-shareholders-meeting-held-on", "source_name": "Moomoo", "published_at": "2026-06-25T22:40:23", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Shareholders Approve 2025 Accounts and Expand Capital-Raising Powers at June 25 Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPSmxLVDdKSExuTnlmSUxONHlBNEpMWU9LZ21LbjZQNXIxd2NNSkU2bTZVTEp5WUZDVDF3RHpfUU9VZ09oNlVOdUg2VlROMkpqa05hVU4tbUQyNjZ2OEk2Wk1QUno0ZXR3TW5ocXFLcW1jdFQ5MFNESVNsQzIxYmE1UWxYZHlhNzNBZkF5VDh1TV9Ic0NHRWhuc0dSVTIzRnU4V2tIdUtxTmlnQzdBeE9iMTYyYkF4c2RTd3RBU2o4b2drWFd4V2NXRExzNHVRc0NBbUw4dmtwZVJxRG1zRUp0WFdSVQ?oc=5", "source_name": "TipRanks", "published_at": "2026-06-25T21:30:41+00:00", "published_display": "25 Jun 2026 21:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) meeting backs capital issuance mandates but rejects employee savings share plan", "summary": "Cellectis S.A. held its Combined General Meeting of Shareholders on June 25, 2026, where key financial items and capital increase delegations, including an \u201cat-the-market\u201d equity financing program on the U.S. market, were approved with strong shareholder support. Shareholders als", "url": "https://www.stocktitan.net/sec-filings/CLLS/6-k-cellectis-s-a-current-report-foreign-issuer-9221cfa967a0.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:08", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Cellectis S.A. Current Report (Foreign Issuer) | CLLS SEC Filing - Form 6-K", "summary": "Cellectis S.A. filed a Form 6-K reporting the results of its shareholders' general meeting held on June 25, 2026. The company announced that resolutions 1 through 29 were adopted, while resolution 30 was rejected, aligning with the board of directors' recommendations. Approximate", "url": "https://www.stocktitan.net/sec-filings/CLLS/6-k-cellectis-s-a-current-report-foreign-issuer-e3049933ddcc.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:41:08", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis SA (CLLS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cellectis SA (CLLS), highlighting its current earnings forecast score, average price target from analysts, and expected revenue for the next quarter. It details analyst ratings, revealing a \"Buy\" trend based on 7 analysts, and includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clls/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:53", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) 10K Form and Latest SEC Filings 2026", "summary": "This article provides an overview of Cellectis (CLLS) SEC filings, including a historical record of documents submitted since 2017. It details the types of filings such as 10-K, 10-Q, and 8-K, explaining their significance for investors. The article notes that Cellectis's most re", "url": "https://www.marketbeat.com/stocks/NASDAQ/CLLS/sec-filings/", "source_name": "MarketBeat", "published_at": "2026-06-12T03:09:34", "published_display": "12 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis reports strong CAR-T cancer trial data at EHA 2026", "summary": "Cellectis (NASDAQ:CLLS) presented highly encouraging clinical trial data at the EHA 2026 Congress for its gene-edited, off-the-shelf CAR-T cancer therapies. The company reported a 100% overall response rate for its lead asset, lasme-cel, in a target group of leukemia patients, wi", "url": "https://grafa.com/en/news/united-states/cellectis-cancer-car-t-data-eha-leukemia-lymphoma", "source_name": "grafa.com", "published_at": "2026-06-11T12:39:51", "published_display": "11 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis CAR-T trials show responses in heavily pretreated blood cancers", "summary": "Cellectis presented final Phase 1 results for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia and preliminary data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026. Lasme-cel achieved a 100% overall response rate in the target Phase ", "url": "https://www.stocktitan.net/news/CLLS/cellectis-presents-final-phase-1-results-of-lasme-cel-and-5f46wwlvd8bl.html", "source_name": "Stock Titan", "published_at": "2026-06-11T06:39:51", "published_display": "11 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress", "summary": "Cellectis presented final Phase 1 data from the BALLI-01 clinical trial for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), showing a 100% overall response rate in the target Phase 2 population. Additionally, preliminary results from the NATHALI-", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310207/0/en/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-eti-cel-at-eha-2026-congress.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T06:39:51", "published_display": "11 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at ...", "summary": "Cellectis presented final Phase 1 data for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and preliminary data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) at the EHA 2026 Annual Congress. The lasme-cel trial showed ", "url": "https://www.caledonianrecord.com/cellectis-presents-final-phase-1-results-of-lasme-cel-and-preliminary-results-on-eti-cel/article_0acd33b4-1689-52a4-904d-19013a432ae6.html", "source_name": "Caledonian Record", "published_at": "2026-06-11T06:39:51", "published_display": "11 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biggest stock movers Wednesday: CBRL, CLLS, SMCI, trucking stocks, and more (SMCI:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNa3V5YURYTDk4RzRmak1hRE5XTzhOQkZlekt5WTB1T2xDLUhQSTBsVXJVMEd5c1YxS21qNDgxMldpeDlhbWpkTFRlemlTVXNySmNUYUMtWFJGZnBQQURKZWJHVVNaVG02dngxR3l0YThfcU9VWFAyeXgxUGE1SVJfT2swbkRUbVBWQW90cVd3bG1EQld3ZktWZ0doZVpUaVRFMWhJNE1TQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis: FDA Grants RMAT Status to Lasm\u00e9-cel for B-Cell ALL Leukemia", "summary": "The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status to Cellectis' lasm\u00e9-cel, an allogeneic CAR-T candidate, for treating relapsed or refractory B-cell acute lymphoblastic leukemia. This designation is based on promising phase 1 data from the BALLI-01 trial, p", "url": "https://www.ideal-investisseur.fr/en/stock-news/cellectis-fda-grants-rmat-status-to-lasme-cel-for-b-cell-all-leukemia/20642.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-10T07:10:56", "published_display": "10 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQelRyblNBOE01OEh0TlZnYkJJRGE2UEl0RW1nZ0RxeHk3aWpmTU9iUllYY0F0N0FMR3A4VVJEYl9GT0NSdzBObloyVTBnQmZHQkZBdkhFVTNCdHQyZkRjOTh2V0xXNUp1cDJPUFFSdUxlSkpHd0t3TkJvUWlPdDhyd3c4Mm81QTdLUFVBaTdqYU1LNVpPTndiX1dQZWcxOVNlMkl3OTFoVko2MXJLVkZzbWRsQUliemJSMHRWTTJQVVpUZw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis now has 100,691,658 shares and 106,134,467 voting rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQkg4UndUcFVJUHNzQ1JPNmk2bk1fNGlmQ19SNENiTWYzcFB0ZW5oMC1jdzVJOTUxZWxGWUsteU9DNjhMQVBhcWV4TUNfVzhORjZFT25yVnVLSGFaZnphc2tQdGhRR29OQWJoUFVwbTJiNVFudVl2aFpORWRIX0xIb3FNZFJjeTdNVXZQLXU3cjl6Q3pHc0hsSVR5NFEwVUNkZnJIVEdVN2FGNzREdVBj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Slides 3% as Biotech Faces Resistance Near $3.70 - Overbought Signal Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQNUJobHYzR0JELVRNdEV4X1IzRkprYWJOeVZobEE3R0ljcDJDYWtOSF9hT0xMNzB2V0FxTzBNcGtMM18tcjI3bXg0SURubGFFQ1B2VHcwTXl5ZFlpZ0E3LWZwUG91ejRHRU5XT3JTSUVKYU15Ni1Kek9yWlRPNVkzSjNVV0pfbnZGR3gtbXUyNTYwYTNxRFlmY0E2NVJIQmlUOTJyeA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene-editing biotech Cellectis plans June 25 shareholder meeting in Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPMmNreTFZNF85bEI0QmwyM3o5VTczM2lPRzlTWFRpQkNTRTBORUFnbjYyMmRRWnc4QWJMeXpDYS1Sc2NLR3VsNlYwY3FOVFhCcDNxS1VwWXRFNTlwUWQxTTA3bFg0Tm9UMUV3VmFXdWNqUXNoOFpZclBoaXBZd1lPc0FXNUphYmZYLXNsRTBVcGF1djNuTmZ4em9CeTVoWUdkS1NIeU54MVB1UlB2dlI0cnFCbmRwUTBSZWJKZjcxQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis stock rating held at outperform on allogeneic platform", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQN0I2VFNTNHpONE12eFkwemt2VzJ3RzJpb1lsOGYzd3dHdHdESDZXbVBvY0ZpUFRmSGFWUlRFa0dYUHJjNGVMYmdORmUydU9QejBxWUJRM3ZTbzg4U0p1ZlNGakNDd2ZfOTRNdVFROEt4WDVOZENGa21NRXY3bklFOW43ci1CcnF4YkhHZDdoSm12QVcyWTBybndSY1lHSWtOUUlTNkZKRE9UR2F5TkV4UUI3Y2pHLUx0b3hhcVVIWjNxQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNRjRNdzRzX1JZWnlEYmk5cE82RE9aWi1menNIaGYyYXFhMU1CU0F5LVZuX2NmN3owOWlBTnozX0dlOFRuTkxLMVhBNjEyYUk1MHZyUS0wOElNYUljWFdCYTgya3BZbnhUVVlzcmpKSG1wWG9xbW1SZ3llUE5ERVp6dnRlVzlUT0pIV05FbE5UdkVXY3J4cG81SnBSTQ?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca, Cellectis targeted in patent lawsuit over gene-editing technology", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQbXQyT3hRUGZVd0FBNjdhOGVMeVFhTm90d3lrMnVZNExaN2NQZWdLWTFCeTJRb3hwamd1UHdEaVpQeW1zTVNNX3o5ckdTZHhtdzBMWWtsRU96R0FDZXhtbDRqT1Q0VzB6d1pudVRabWNWdWN0dmFmS2I1YnZ1V3NkQ2luRW5XQ08zY2JJWmNQc1B4Umd5b1doS21HTFpEdWw3ZTVlRXJBOWdKRGI0MDJpQk9XSnN6dm5WOFIzYnN3NG9JWDBlblE?oc=5", "source_name": "Reuters", "published_at": "2025-09-26T07:00:00+00:00", "published_display": "26 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Stock Forecast and Price Target 2026 $CLLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE82cGMtNzE2UG9LamZvMENoSWg3VDRYZkZBVGVMYmNGMEMzRUR5b2dpUnMtSm1MVnpTaF9lbTc1MWk0MkE2cWd2MmxTVEhOdUlxVEVNMnVGSnZBV0tRdWdYc0ZaX0tBdw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:07:11+00:00", "published_display": "11 May 2024 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9rSjlsb3JLdExuT2g0XzhZY1c4N1IxN2t5RDdPU3BDSFJhUDJtRFBPWS1kdzNkNE5HNTZjbk9HaWZfNW54bXpFR04wbmtZQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-02T23:41:02+00:00", "published_display": "02 Sep 2020 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectis (CLLS) Stock Price, News & Analysis $CLLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE44ZWE1M3RvZjlVVGFIUjZRbC1BMjBLU3gzcVpyV3lkc0Z1Ynctc0ozVjREdWxZQVh5aE9HZ0R2c3NmTEk3QlNQc3NiYXJYX2JmZGNPVGpkakpoUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T02:21:20+00:00", "published_display": "12 Aug 2016 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 49, "sentiment_summary": {"positive": 10, "negative": 3, "neutral": 36, "score": 54, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.9, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 10.86, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.9, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.99, "latest_week": "2026-07-10", "one_week_move": -9.4, "four_week_move": -3.2, "twelve_week_move": -32.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.760583, "market_dynamics_buy_signal": false, "relative_strength": -28.592333, "fair_value_gap": 15.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 40.1995, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.4% over one week, -3.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 7}, {"label": "MarketBeat", "count": 4}, {"label": "dars.gov.et", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Barchart", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 22}, {"label": "Market update", "count": 21}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.4% over one week, -3.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of \"Moderate Buy\" from Brokerages"}], "updated_at": "2026-07-17T13:31:53.739176+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}